Trial Profile
Multinational, multicenter, prospective, long-term safety and efficacy follow-up study after Autologous Cultivated Limbal Stem Cells Transplantation (ACLSCT) for restoration of corneal epithelium in patients with limbal stem cell deficiency due to ocular burns (HOLOCORE-FU)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 May 2023
Price :
$35
*
At a glance
- Drugs Autologous corneal epithelial stem cell therapy Chiesi/Holostem Terapie Avanzate (Primary)
- Indications Limbal stem cell deficiency
- Focus Adverse reactions
- Acronyms HOLOCORE FU
- Sponsors Chiesi Farmaceutici; Holostem Terapie Avanzate
- 24 May 2023 Status changed from active, no longer recruiting to completed.
- 05 May 2023 The trial has been completed in Germany,according to European Clinical Trials Database record.
- 05 May 2023 The trial has been completed in Poland, according to European Clinical Trials Database record.